Trials / Completed
CompletedNCT00627848
Rivastigmine in Mild Alzheimer's Disease, FMRI Study
Effect of Rivastigmine on FMRI in Mild Alzheimer's Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Kuopio University Hospital · Academic / Other
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rivastigmine | Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions. |
Timeline
- Start date
- 2007-03-01
- Primary completion
- 2008-12-01
- Completion
- 2008-12-01
- First posted
- 2008-03-03
- Last updated
- 2011-10-28
Locations
1 site across 1 country: Finland
Source: ClinicalTrials.gov record NCT00627848. Inclusion in this directory is not an endorsement.